Terran Biosciences' founder and CEO Sam Clark talks about big opportunities for prodrug development in 2025, the importance of a strong medicinal chemistry team, and a potential increase in M&A ...

The pharmaceutical industry sits on a treasure trove of data, brimming with the potential to revolutionize drug development, enhance patient care, and optimize commercial strategies. Yet, this vast ...

The life sciences industry contributed nearly $4 billion to the U.S. economy in 2021 and is expected to continue growing an average 7% to 8% per year over the next five years. With an increasing ...

Life Biosciences' Jerry McLaughlin and Forge Biologics' John Maslowski explain the importance of transparency and collaboration when encountering manufacturing speed bumps.

Life Biosciences' Jerry McLaughlin and Forge Biologics' John Maslowski discuss their companies’ partnership, Life’s pipeline, and Columbus’ biotech hub.

Biopharma guru Allan Shaw speculates on the risks and benefits that the incoming Trump administration could bring to the industry.

Revolo’s plans for 2025 include expanding clinical trials for its lead eosinophilic esophagitis candidate and developing a sublingual delivery method.

Muminah is a teenager living with vernal keratoconjunctivitis (VKC), a rare condition characterized by inflammation of the conjunctiva, the eye’s outer membrane. In this video, Muminah shares her ...

Without doubt, the grand and collaborative experiment that was the mRNA COVID vaccine contributed mightily to the pandemic response and continues to save lives untold. It also demonstrated the ...

Dr. Tal Zaks joins the Business of Biotech for the second part of "Story Time With Tal," discussing his transition from Moderna's CMO during the COVID-19 pandemic to co-founding Exsilio Therapeutics, ...

Foresite Labs' Vik Bajaj, Ph.D. shares how massive data sets are essential to shortening drug development timelines and creating innovative therapeutics.

Woody Bryan, Ph.D. has founded several biotech companies during his career, and he explains how his journey from scientist to business development prepared him for the C-suite.